Precision oncology: separating the wheat from the chaff
被引:31
|
作者:
Remon, Jordi
论文数: 0引用数: 0
h-index: 0
机构:
HM Delfos, Ctr Integral Oncol Clara Campal Barcelona, Med Oncol Dept, Barcelona, SpainHM Delfos, Ctr Integral Oncol Clara Campal Barcelona, Med Oncol Dept, Barcelona, Spain
Remon, Jordi
[1
]
Dienstmann, Rodrigo
论文数: 0引用数: 0
h-index: 0
机构:
Hosp Valle De Hebron, Oncol Data Sci ODysSey Grp, Barcelona, SpainHM Delfos, Ctr Integral Oncol Clara Campal Barcelona, Med Oncol Dept, Barcelona, Spain
Dienstmann, Rodrigo
[2
]
机构:
[1] HM Delfos, Ctr Integral Oncol Clara Campal Barcelona, Med Oncol Dept, Barcelona, Spain
[2] Hosp Valle De Hebron, Oncol Data Sci ODysSey Grp, Barcelona, Spain
Precision oncology based on next-generation sequencing (NGS) test is growing in daily clinical practice. However, the real impact of this strategy in patients' outcome on a large scale remains uncertain. In this review, we summarise existing literature on this topic, limitations for broad NGS implementation, bottlenecks in genomic variant interpretation and the role of molecular tumour boards.